We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDX icon
76
Aldeyra Therapeutics
ALDX
$92.9M
$1.67M 0.22%
+375,000
New +$1.49M
FNCH
77
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$1.66M 0.22%
11,017
+493
+5% +$114K
VKTX icon
78
Viking Therapeutics
VKTX
$3.7B
$1.6M 0.21%
532,429
+31,787
+6% +$114K
CLVS
79
DELISTED
Clovis Oncology, Inc.
CLVS
$1.56M 0.21%
772,339
-340,330
-31% -$669K
AUTL
80
Autolus Therapeutics
AUTL
$397M
$1.55M 0.2%
372,217
-172,602
-32% -$726K
TARA icon
81
Protara Therapeutics
TARA
$220M
$1.51M 0.2%
296,426
+17,170
+6% +$90.3K
RNTX
82
Rein Therapeutics
RNTX
$63.1M
$1.49M 0.2%
145,104
+6,925
+5% +$62.7K
RCOR
83
DELISTED
Renovacor, Inc.
RCOR
$1.46M 0.19%
343,283
+381
+0.1% +$2.28K
MGNX icon
84
MacroGenics
MGNX
$235M
$1.45M 0.19%
164,119
+8,072
+5% +$89.1K
ELDN icon
85
Eledon Pharmaceuticals
ELDN
$261M
$1.43M 0.19%
362,537
+17,959
+5% +$69.6K
MRUS
86
DELISTED
Merus
MRUS
$1.42M 0.19%
53,703
+2,796
+5% +$74.9K
NTBL
87
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$1.4M 0.18%
23,736
+1,141
+5% +$58.1K
CMMB
88
Chemomab Therapeutics
CMMB
$11.4M
$1.29M 0.17%
67,026
+710
+1% +$14K
SYBX
89
DELISTED
Synlogic
SYBX
$1.25M 0.16%
34,652
+2,397
+7% +$74.7K
ACET icon
90
CALL
Adicet Bio
ACET
$85.2M
$1.24M 0.16%
3,881
-8,619
-69% -$1.98M
ANEB
91
DELISTED
Anebulo Pharmaceuticals
ANEB
$1.23M 0.16%
181,199
+8,890
+5% +$60.9K
TAOX
92
Tao Synergies Inc
TAOX
$24.6M
$1.19M 0.16%
6,129
+304
+5% +$57.5K
BLCM
93
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.13M 0.15%
523,348
+26,592
+5% +$43.2K
NUVB icon
94
Nuvation Bio
NUVB
$2.2B
$1.12M 0.15%
213,310
+13,310
+7% +$74.8K
AUPH icon
95
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.08M 0.14%
87,071
+4,736
+6% +$73.2K
PHAT icon
96
Phathom Pharmaceuticals
PHAT
$708M
$1.07M 0.14%
78,550
+3,990
+5% +$64.5K
CASI
97
DELISTED
CASI Pharmaceuticals
CASI
$1.07M 0.14%
132,016
+9,709
+8% +$76.3K
DBVT
98
DBV Technologies
DBVT
$799M
$1.05M 0.14%
31,694
+683
+2% +$10.3K
ASND icon
99
Ascendis Pharma A/S
ASND
$16B
$1.03M 0.14%
8,763
+363
+4% +$42K
BCLI
100
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.02M 0.13%
20,277
+974
+5% +$47.8K
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.